PTA-Adhoc: Dr. Hönle AG: Hönle Group generates operating result of € 2.7 million in the first quarter and confirms the annual forecast
Gilching 20.Feb.2023
Public disclosure of inside information according to article 17 MAR
Gilching (pta038/20.02.2023/16:05) - According to preliminary figures, Hönle Group's sales revenues in the first three months of financial year 2022/2023 came to € 30.6 million and were thus 8.4% down from the previous year's level. Sales generated with air disinfection equipment, in particular, dropped from € 5.2 million in the previous year to € 0.7 million in the reporting year in the course of an easing pandemic situation.
At € 2.7 million, the operating result (EBIT) fell short of the previous year's figure of € 4.5 million. It should be noted, however, that the operating result reported for the previous year includes one-off effects of € 1.8 million from the sale of a company building. Despite clearly lower sales revenues earned in the air disinfection business, the operating result was thus on par with the adjusted previous year's result of € 2.7 million.
Earnings before tax (EBT) amounted to € 2.4 million after € 4.2 million in the prior year period. The consolidated profit after income taxes amounted to € 1.9 million (PY: € 3.2 million). Earnings per share decreased from € 0.53 to € 0.32, and the net return on sales stood at 6.3% (PY: 9.5%) in the first quarter.
Outlook
Promising customer projects covering all three business segments and a favourable orders position provide the basis for Hönle Group's positive development although the contribution to sales and earnings in the second quarter is expected to be lower than in the first quarter. The adjustment of sales prices will help to improve gross profit margins in the course of financial year 2022/2023. Moreover, the sale of Raesch Quarz (Germany) GmbH will lead to positive earnings and liquidity effects at Group level.
In all, the Management Board expects Hönle Group's sales revenues in financial year 2022/2023 to be below the previous year's level (€ 126.5 million) and the operating result to be significantly above the adjusted operating result for the previous year (€ 8.9 million).
The Quarterly Statement 2022/2023 will be published on 24 February 2023 as planned and can then be viewed on the Internet under https://www.hoenle.com/investor-relation/financial-information# reports.
About Hönle
Dr. Hönle AG, headquartered in Gilching, Germany, is a leading supplier of industrial UV technology. With more than 600 employees, the Hönle Group develops innovative solutions for various fields of application. One focus of business activities is the development and sale of industrial adhesives and casting compounds. The company also manufactures equipment for the drying of inks and coatings , adhesives and plastics curing, as well as for the disinfection of air, water and surfaces sterilisation, and sunlight simulation. In addition, the corporate group produces UV lamps and quartz glass products for disinfection and drying processes, among others. The Hönle Group supplies technology and global market leaders worldwide and is represented in more than 20 countries by its own companies and partner companies.
(end)
emitter: Dr. Hönle AG
address: Nicolaus-Otto-Str. 2, 82205 Gilching
country: Germany
contact person: Peter Weinert
phone: +49 8105 2083 173
e-mail: peter.weinert@hoenle.de
website: www.hoenle.de
ISIN(s): DE0005157101 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate